Plain-English translation of NCT05147688 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) — special healing cells grown from umbilical cord tissue — given as a single intravenous infusion to treat pulmonary diseases. Researchers want to understand whether this treatment is safe and whether it can help improve symptoms in people with lung conditions like asthma or chronic obstructive pulmonary disease (COPD). The medication is donated by others and grown in a laboratory, so you don't need your own cells.
Lung diseases like asthma and COPD can cause significant suffering and limit quality of life, and current treatments don't work for everyone. This trial explores whether the anti-inflammatory and healing properties of stem cells might offer a new option for people whose symptoms aren't adequately controlled by existing medications.
You likely qualify if…
You likely don't qualify if…
You will receive one intravenous infusion of 100 million stem cells. Before treatment, you'll have a medical evaluation within one month. After the infusion, you'll return for follow-up visits at 1 month, 6 months, 1 year, 2 years, 3 years, and 4 years to check for safety and to see if the treatment is helping your lung symptoms. The study will monitor you closely to make sure the stem cell infusion is well-tolerated and effective.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Antigua and Barbuda
Phase
Safety & dosing
Sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Enrollment target
~20 participants
Started
December 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in April 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.